January 26, 2026
“…Acumen Pharmaceuticals (ABOS)… With a major catalyst ahead and ABOS shares trading at $1.98, Stifel’s 5-star analyst Paul Matteis thinks now is the right time to make a move… To this end, Matteis rates ABOS a Buy, and his $10 price… Continue Reading…

Recent Comments